Evidence at a glance.
Each therapy is rated by the strength of clinical evidence — from large human trials down to primarily preclinical research. Ratings are educational; a licensed provider decides what may be appropriate for you.
Large Human Trials
A GLP-1 receptor agonist commonly evaluated for medical weight management and metabolic support.
Dual GIP/GLP-1 receptor agonist evaluated for weight and cardiometabolic health.
GHRH analog with FDA approval for a specific HIV-related indication; sometimes discussed off-label.
Multiple Human Studies
GHRH and GHRP combination studied for pulsatile growth hormone release.
Coenzyme central to cellular energy, sirtuin activation, and DNA-repair pathways.
Immunomodulatory peptide studied for T-cell function.
GHRH analog studied for stimulation of the body's own growth hormone.
Melanocortin receptor agonist with an FDA-approved indication in premenopausal women; other uses discussed with providers.
Endogenous tripeptide antioxidant used clinically in select settings.
Investigational triple agonist (GLP-1 / GIP / glucagon) studied for weight management. NOT FDA-approved.
Small Human Studies
Modified GH fragment studied for lipolysis in research settings.
Neuropeptide sometimes discussed for mood, bonding, and intimacy support in provider-directed protocols.
Orally active ghrelin receptor agonist studied for GH/IGF-1 secretion.
Copper-binding tripeptide studied for skin and hair follicle signaling.
Mitochondrial-derived peptide studied in metabolic homeostasis research.
Neuroendocrine peptide studied in hypothalamic-pituitary-gonadal signaling.
Compounded topical/injectable blend discussed for aesthetic and repair applications.
Compounded aesthetic blend evaluated case-by-case.
Primarily Preclinical
Peptide fragment studied primarily in preclinical models for tissue repair.
Tetrapeptide studied for telomerase activity and circadian rhythm.
A compounded blend of two Russian-developed neuropeptides studied individually in preclinical and limited human models for cognitive and stress-regulatory effects. Neither is FDA-approved.
A branded compounded blend combining BPC-157 and TB-500, two research peptides individually studied in preclinical models for tissue repair. Neither component is FDA-approved; this specific combination has not been evaluated in clinical trials as a combination.